The Effect of Liposomal Bupivacaine on Post Operative Pain and Narcotic Use After Bariatric Surgery
| Status: | Active, not recruiting |
|---|---|
| Conditions: | Post-Surgical Pain |
| Therapuetic Areas: | Musculoskeletal |
| Healthy: | No |
| Age Range: | 18 - 65 |
| Updated: | 2/9/2019 |
| Start Date: | December 4, 2017 |
| End Date: | January 2020 |
This study is prospective, randomized trial in which the efficacy of liposomal bupivacaine
(Exparel®) is compared to standard bupivacaine local surgical site injection in reducing
total IV and oral morphine equivalents required after laparoscopic bariatric surgery.
Liposomal bupivacaine is a 72-hour bupivacaine that is slowly released from tissue over the
course of three days. Having a long acting local anesthetic should provide better pain
control than conventional bupivacaine which has a 3.5-hour half-life. In some studies, the
use of liposomal bupivacaine has been shown to decrease pain and narcotic use after surgery.
This has not yet been studied in bariatric patients and the use of liposomal bupivacaine can
potentially improve patient post-operative pain control, decrease narcotic use, decrease
hospital length of stay and readmission rates and improve patient satisfaction after
bariatric surgery.
(Exparel®) is compared to standard bupivacaine local surgical site injection in reducing
total IV and oral morphine equivalents required after laparoscopic bariatric surgery.
Liposomal bupivacaine is a 72-hour bupivacaine that is slowly released from tissue over the
course of three days. Having a long acting local anesthetic should provide better pain
control than conventional bupivacaine which has a 3.5-hour half-life. In some studies, the
use of liposomal bupivacaine has been shown to decrease pain and narcotic use after surgery.
This has not yet been studied in bariatric patients and the use of liposomal bupivacaine can
potentially improve patient post-operative pain control, decrease narcotic use, decrease
hospital length of stay and readmission rates and improve patient satisfaction after
bariatric surgery.
Inclusion Criteria:
- All patients undergoing elective laparoscopic sleeve gastrectomy or Roux-en-Y gastric
bypass surgeries.
- Fulfills NIH criteria for bariatric surgery
Exclusion Criteria:
- Patients deemed not a candidate for laparoscopic bariatric surgery
- Patients with previous bariatric or gastric surgeries.
- BMI <35 and > 60 kg/m2
- Preoperative inability to ambulate and confined to wheelchair.
- American Society of Anesthesiologist (ASA) score >3
- Concurrent ventral hernia repair or intraoperative extensive lysis of adhesions
- Not able to understand informed consent, or unwilling to sign consent.
- Not able to understand and read English
- Currently pregnant or lactating.
- Age <18 or >65
- Patients intolerant of opiates, NSAIDS, acetaminophen or local anesthetics.
- Patients requiring opiate use within 30 days prior to time of surgery.
- Patients with reported use of narcotics greater than 2 weeks in preceding year before
surgery.
- Patients with history of substance abuse, alcohol addiction
- Patients with diagnosis of chronic pain, history of fibromyalgia, chronic regional
pain syndrome (dystrophic pain syndrome).
- Bupivacaine use within 96 hours before operation
- Prisoners
- Bariatric surgery operation >3 hours.
- More than 5 laparoscopic incision sites used during surgery, conversion to open
operation, placement of a feeding tube or drain.
- Patients with renal failure or hepatic failure.
We found this trial at
1
site
15 East Audubon Drive
Fresno, California 93720
Fresno, California 93720
Phone: 559-261-4500
Click here to add this to my saved trials
